Has Gregory Burzynski received payments from drug or device companies?

Yes. Drug and device makers reported $5,217 in general payments to Gregory Burzynski across 277 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gregory Burzynski did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gregory Burzynski come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gregory Burzynski

Internal Medicine · Houston, TXNPI 1952592131

Payments from drug & device makers

$5,217in general payments, 2019–2025

Across 277 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Indivior Inc.$567
Gilead$464
Lilly USA, LLC$303
E.r. Squibb & Sons, L.L.C.$257
Viiv Healthcare Company$249
Johnson & Johnson$241
plus $3K from 53 others

$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Indivior Inc.$150

What the payments were for

Food & beverage$5,09498%
Education$1232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Indivior Inc.	26	$567
Gilead	29	$464
Lilly USA, LLC	16	$303
E.r. Squibb & Sons, L.L.C.	15	$257
Viiv Healthcare Company	9	$249
Johnson & Johnson	9	$241
AbbVie(2 entities)	12	$217
Tempus AI, Inc	8	$188
Abbott	20	$149
Amgen	8	$143
MDD US Operations, LLC	13	$134
Clovis Oncology, Inc.	7	$133
Alkermes, Inc.	7	$128
US Oncology Corporate, Inc.	3	$128
Eisai Inc.	8	$127
AstraZeneca	8	$120
Ablative Solutions, Inc.	1	$115
Kowa Pharmaceuticals America, Inc.	2	$114
Boehringer Ingelheim	6	$114
Pfizer	5	$101
Verastem, Inc.	1	$67
Biohaven Pharmaceutical Holding Company Ltd.	4	$67
Sobi, Inc	2	$62
Novo Nordisk	4	$61
Kyowa Kirin, Inc.	4	$56
Takeda Pharmaceuticals U.S.A., Inc.	3	$56
Braeburn Inc.	2	$50
Lexicon Pharmaceuticals, Inc.	3	$47
Idorsia Pharmaceuticals US Inc	2	$43
Orexo US, Inc.	3	$43
Biohaven Pharmaceuticals, Inc.	2	$43
Merck	2	$39
Taiho Oncology, Inc.	2	$36
Xeris Pharmaceuticals, Inc.	2	$35
Astellas Pharma US Inc	2	$33
Axsome Therapeutics, Inc.	2	$32
USWM, LLC	2	$31
Dova Pharmaceuticals	2	$30
Adaptive Biotechnologies Corporation	1	$29
Exact Sciences	1	$26
Sanofi	1	$25
Epizyme, Inc.	1	$24
Day One Biopharmaceuticals	1	$23
Pharmacyclics LLC, An Abbvie Company	1	$23
Boston Scientific	1	$23
Cleerly, Inc.	1	$23
Tesaro, Inc.	1	$23
Bayer	1	$21
Amneal Pharmaceuticals LLC	1	$20
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$17
Mirati Therapeutics, Inc.	1	$16
Inspire Medical Systems, Inc.	1	$15
Supernus Pharmaceuticals, Inc.	1	$15
Foundation Medicine, Inc.	1	$14
Currax Pharmaceuticals LLC	1	$14
Vyera Pharmaceuticals, LLC	1	$13
Medicure Pharma Inc.	1	$12
Avanir Pharmaceuticals, Inc.	1	$12
Romark Laboratories, LC	1	$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Seglentis$101

How this compares

$5,217 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	25	$4,611
Rosuvastatin Calcium	21	$178
Amlodipine Besylate	21	$109
Tamsulosin Hcl	11	$105
Eszopiclone	12	$90
Losartan Potassium	11	$80
Tizanidine Hcl	15	$74
Metformin Hcl ErMetformin Hcl	13	$73
Alprazolam	14	$53
Atorvastatin Calcium	11	$53
Lisinopril	19	$45
Azithromycin	13	$30
Hydrochlorothiazide	12	$21

Paid to pharmacies, not to this prescriber.

Other internal medicine in Houston

Jan BurgerHouston$47.3M
Nitin JainHouston$33.2M
Aung NaingHouston$30.6M
Preetesh JainHouston$19.5M
Paolo StratiHouston$19.2M
Nicholas ShortHouston$17.6M
Isabella GlitzaHouston$14.8M
Murtaza MussajiHouston$13.1M
Hussein TawbiHouston$12.6M
Hans LeeHouston$11.7M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →